Liquid biopsy for minimal residual disease detection in leukemia using a portable blast cell biochip
Author(s)Khoo, Bee Luan; Shang, Menglin; Ng, Chin Hin; Lim, Chwee-Teck; Chng, Wee Joo; Han, Jongyoon; ... Show more Show less
MetadataShow full item record
Long-term management for leukemia is challenging due to the painful and invasive procedure of bone marrow (BM) biopsy. At present, non-invasive liquid (blood) biopsy is not utilized for leukemia, due to lower counts of leukemia blast cells in the blood. Here, we described a robust system for the simultaneous detection and enrichment of rare blast cells. Enrichment of blast cells was achieved from blood with a one-step microfluidic blast cell biochip (BCB) sorting system, without specific targeting of proteins by antibodies. Non-target cells encountered a differential net force as compared to stiffer blast cells and were removed. The efficiency of the BCB promotes high detection sensitivity (1 in 10<jats:sup>6</jats:sup> cells) even from patients with minimal residual disease. The procedure was validated using actual blast cells from patients with various types of leukemia. Outcomes were compared to current evaluation standards, such as flow cytometry, using BM aspirates. Blast cell detection efficiency was higher in 55.6% of the patients using the BCB as compared to flow cytometry, despite the lower concentrations of blast cells in liquid biopsy. These studies promote early-stage detection and routine monitoring for minimal residual disease in patients.
DepartmentMassachusetts Institute of Technology. Department of Electrical Engineering and Computer Science; Massachusetts Institute of Technology. Department of Biological Engineering; Singapore-MIT Alliance in Research and Technology (SMART)
npj Precision Oncology
Khoo, Bee Luan et al. "Liquid biopsy for minimal residual disease detection in leukemia using a portable blast cell biochip." npj Precision Oncology 3, 1 (December 2019): 30
Final published version